The prices of targeted oncology therapies have grown substantially, but revenues have not. This is due in part to large declines in per-drug patient counts.
Hans-Peter Goertz, MPH
Advertisement
Articles by Hans-Peter Goertz, MPH
Advertisement
Latest Updated Articles
- Understanding Price Growth in the Market for Targeted Oncology Therapies
Published: June 14th 2019 | Updated:
Advertisement
Advertisement
Trending on AJMC
1
Trump Administration Flags Potential Link Between Prenatal Acetaminophen Use, Autism
2
More Effective CKD Strategy Could Have Health, Societal Benefits
3
Childhood Cancer Awareness Month Spotlights Barriers That Persist in Care
4
Designing Value-Based Care Programs Around Arrhythmias
5
